{
    "clinical_study": {
        "@rank": "153299", 
        "brief_summary": {
            "textblock": "Intensive chemotherapy is associated with significant thrombocytopenia, often requiring\n      platelet transfusion to maintain platelet counts. This investigational drug has demonstrated\n      the ability to increase platelet counts. This study will test the safety and efficacy of\n      this investigational drug in the prevention of thrombocytopenia in patients with solid\n      tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens\n      requiring platelet transfusion support."
        }, 
        "brief_title": "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia", 
        "completion_date": "September 2002", 
        "condition": [
            "Neoplasms", 
            "Thrombocytopenia", 
            "Multiple Myeloma", 
            "Lymphoma, Malignant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphoma", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Thrombocytopenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have solid tumors, lymphomas or multiple myeloma who are receiving\n             myelosuppressive treatment regimens requiring platelet transfusion support\n\n        Exclusion Criteria:\n\n          -  Patients must not have active bleeding (exclusions do apply) or history of platelet\n             disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "180", 
        "firstreceived_date": "May 21, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00037791", 
            "org_study_id": "98-OTPO-005"
        }, 
        "intervention": {
            "intervention_name": "(PN-152,243)/PN-196,444", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "November 8, 2006", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=98-OTPO-005&StudyName=Safety+and+Efficacy+of+%28PN%2D152%2C243%29%2FPN%2D196%2C444+in+the+Prevention+of+Thrombocytopenia+"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berkeley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94704"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90067"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033-0804"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70115"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "state": "Capital Federal", 
                        "zip": "1406"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "state": "Capital Federal", 
                        "zip": "1114"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico", 
                        "state": "DF", 
                        "zip": "02990"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Mexico"
            ]
        }, 
        "official_title": "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_outcome": {
            "measure": "To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037791"
        }, 
        "secondary_outcome": [
            {
                "measure": "Identify the effect of rhTPO on the number of episodes of severe chemotherapy-induced thrombocytopenia(platelet count <15,000/mm3) and the number of platelet transfusions"
            }, 
            {
                "measure": "Evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhTPO Prophylaxis"
            }, 
            {
                "measure": "Quantify the effect of rhTPO on the occurrence of any bleeding events associated with thrombocytopenia"
            }, 
            {
                "measure": "Assess the likelihood that patients will have adequate hematologic recovery to allow on-time chemotherapy administration in the subsequent cycle"
            }, 
            {
                "measure": "Assess the safety of multiple intravenous doses of rhTPO"
            }, 
            {
                "measure": "Determine the occurrence and clinical implications of any anti-rhTPO antibodies"
            }, 
            {
                "measure": "Evaluate the impact of rhTPO prophylaxis on health economics/cost effectiveness"
            }, 
            {
                "measure": "Evaluate the impact of rhTPO administration on patient quality of life"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 1999", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2006"
    }, 
    "geocoordinates": {
        "Pfizer Investigational Site": "19.433 -99.133"
    }
}